目的探讨ｍｄｒ１基因编码的Ｐ糖蛋白（Ｐｇｐ）在肝细胞癌（ＨＣＣ）及癌周正常肝组织中的表达及其临床意义．方法用免疫组化ＳＡＢＣ法，检测３９例ＨＣＣ及３０例癌周肝组织中Ｐｇｐ表达，分析ＨＣＣ中Ｐｇｐ表达程度和肿瘤主要临床病理特征间的关系．结果Ｐｇｐ表达主要位于肝、肝癌及胆管上皮细胞膜上，少量位于胞质内；肝组织中平均Ｐｇｐ阳性率（５６４％）明显高于癌组织（２６０％，ｕ＝２６５，Ｐ＜００１）；经治病例癌组织Ｐｇｐ表达均在５０％以上；癌组织Ｐｇｐ表达仅和细胞分化有关（χ２＝５８６，Ｐ＜００５）．结论肝脏是内源性耐药器官；经治后肝癌耐药性增强；化疗应选择合理方案 Objective To investigate the expression and clinical significance of Pglycoprotein (Pgp) encoded by mdr1 gene in hepatocellular carcinoma (HCC) and normal liver tissue. Methods Immunohistochemical SABC method was used to detect the expression of Pgp in 39 cases of HCC and 30 cases of liver tissue around the tumor. The relationship between the expression of Pgp in HCC and the main clinicopathological features was analyzed. Results The expression of Pgp was mainly located in the liver, liver and biliary epithelial cell membranes, with a small amount located in the cytoplasm; the average Pgp positive rate (56.4%) was significantly higher in the liver tissue than in the cancer tissue (26.0%, u=2.65, P<001); The expression of Pgp in cancer tissue was over 50% in the treated cases; the expression of Pgp in cancer tissue was only related to cell differentiation (χ2=586, P<005). Conclusion The liver is an endogenous drug resistant organ; the drug resistance of liver cancer is increased after treatment; rational treatment should be selected for chemotherapy